Over 1 million people in North America live with Crohn’s disease (CD) and nearly 25% are diagnosed before 20 years of age.1 Patients with pediatric-onset CD endure a lifelong disease burden with high rates of disease progression, increased risk of recurrent surgery and decreased height potential.2
Over the past two decades, there has been a paradigm shift in the treatment of CD with the development of biologic agents.3,4 While biologics have shown to improve short-term outcomes, it has been difficult to show the long-term benefit of biologic therapy from standard trials. A team of clinicians, statisticians and computer analysts have come together to answer this question.